ARTICLE | Clinical News
Bucillamine: Phase IIa start
December 8, 2014 8:00 AM UTC
At year end, Revive Therapeutics will begin an open-label, U.S. Phase IIa trial to evaluate a high- and moderate-dose of once-daily oral REV-002 in combination with low-dose colchicine for 7 days in a...